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Abstract The CD99 antigen has been implicated in various
cellular processes, including apoptosis in T cells. Previously,
we reported two monoclonal antibodies that recognize di¡erent
epitopes of the CD99 molecule, named DN16 and YG32. In this
study, we investigated the role of each CD99 epitope in T cell
apoptosis. Unlike the DN16 epitope, CD99 ligation via the
YG32 epitope failed to induce T cell death. Surprisingly, how-
ever, the YG32 signal enhanced Fas-mediated apoptosis in Jur-
kat T cells. Augmentation of Fas-mediated apoptosis by YG32
ligation was inhibited by treatment with either of the caspase
inhibitors z-VAD-fmk or z-IETD-fmk, and YG32 ligation ap-
peared to induce Fas oligomerization. These results suggest that
each CD99 epitope plays a distinct role in T cell biology, espe-
cially in T cell apoptosis.
0 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Apoptosis is the process by which cells commit suicide, and
is characterized by distinct morphological and biochemical
changes [1^3]. The transmembrane protein CD95 (Fas,
APO-1) is a death receptor expressed on a variety of cell
types, including lymphocytes, hepatocytes, and cardiac muscle
cells. Cross-linking of surface Fas molecules by the Fas ligand
(FasL, CD95L) or agonistic anti-Fas antibodies activates ap-
optotic death programs [4,5] via homo-oligomerization and
results in the cleavage of several intracellular substrates [6^
8]. Although receptor-mediated death signaling plays a major
role in classical apoptosis, an increasing number of antigens
have been implicated in non-classical, programmed cell death
[9^13]. These include CD45, CD47, CD99, and MHC class I
molecules.
The CD99 (E2 or MIC2) molecule is a leukocyte surface
protein with a molecular weight of 32 kDa encoded by the
MIC2 gene [14], which is located in the pseudo-autosomal
region of the human X and Y chromosomes [15]. Although
the function of the CD99 molecule is still unclear, it has been
implicated in various cellular processes, including homotypic
aggregation, apoptosis [16^19], vesicular protein transport
[20^22], cell adhesion [23], Th1 cell di¡erentiation [24], and
migration of monocytes [25]. Apoptosis induced via the CD99
molecule has been demonstrated in double-positive thymo-
cytes [16] and immature T cell lines [13,19] and appears to
be caspase-independent [13].
A number of monoclonal antibodies (mAbs) that react with
the CD99 molecule have been produced and each mAb rec-
ognizes a di¡erent epitope on CD99 with distinct functions
[13,26]. For example, Pettersen et al. [13] reported that certain
epitopes on the CD99 molecule induced rapid death signaling
in Jurkat E6 cells, suggesting that CD99 is a death receptor.
We previously developed two anti-CD99 mAbs, DN16 and
YG32, which appear to recognize di¡erent epitopes on
CD99 molecules [26,27]. Although the a⁄nity of YG32 to
the CD99 molecule is stronger than that of DN16 [26], most
of our studies were restricted to the DN16 epitope [17,20^
22,28].
To investigate the biological roles of distinct CD99 epitopes
in T cell signaling, we examined the impact of the YG32 epi-
tope in T cell apoptosis. Here, we report that while CD99
ligation via the YG32 epitope did not induce apoptosis,
YG32 signaling enhanced Fas-mediated apoptosis via acceler-
ation of Fas aggregation. Therefore, our results suggest that
each CD99 epitope is involved in T cell death through diver-
gent pathways.
2. Materials and methods
2.1. Cells and reagents
Jurkat T cells were cultured at 37‡C in 5% CO2 in RPMI 1640
medium (Sigma, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT, USA), 50 WM 2-mercaptoethanol
(2-ME), 2 mM L-glutamine, 10 mM HEPES, and 100 U/ml each of
penicillin and streptomycin. The following antibodies against Fas pro-
tein were purchased from the sources shown: clone CH11 (Medical
and Biological Laboratory, Nagoya, Japan), and clone C20 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Anti-mouse Ig antise-
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rum coupled to horseradish peroxidase (HRP) was from Dako Cyto-
mation (Glostrup, Denmark). The caspase inhibitors z-VAD-fmk and
z-IETD-fmk were from Calbiochem (La Jolla, CA, USA). Anti-CD99
mAbs, clones YG32 and DN16, were purchased from DiNonA
(Seoul, Korea). FITC-labeled annexin V was purchased from BD
Biosciences (San Diego, CA, USA) and 7-aminoactinomycin D (7-
AAD) and 3,3P-dihexyloxacarbocyanine iodide (DiOC6) were ob-
tained from Sigma.
2.2. Antibody treatment and £ow cytometric analysis
Jurkat cells were plated in 24-well plates at 2U105 cells/well in a
¢nal volume of 1 ml of RPMI 1640 medium. These cells were treated
with 2 or 10 Wg/ml anti-CD99 mAb (YG32 or DN16) with or without
anti-Fas Ab (CH11). At the indicated times, cells were harvested and
then analyzed for apoptosis or subjected to immunoblotting. To de-
tect apoptosis by £ow cytometry, annexin V-FITC and 7-AAD were
used. To evaluate the mitochondrial potential (vim) by £ow cytome-
try, the cationic lipophilic £uorochrome DiOC6 was used. Flow cyto-
metric analysis was performed using a FACSCalibur1 £ow cytometer
(Becton-Dickinson, Mountain View, CA, USA) and the data were
analyzed using CellQuest1 (Becton-Dickinson) software.
2.3. Assay for caspase activity
To detect caspase activity, the Caspase 3 Activity Assay kit (Roche,
Mannheim, Germany) was used. Cytosolic extracts from 2U106 cells
were incubated in anti-caspase 3 antibody-coated plates, followed by
washing and adding the £uorescent tetrapeptide substrate (Ac-DEVD-
AMC). Free aminomethylcoumarin (AMC) accumulation, which re-
sulted from cleavage of the aspartate^AMC bond, was monitored in
each sample in 96-well microtiter plates using a £uorometer at 400 nm
excitation and 505 nm emission wavelengths.
2.4. Treatment with caspase inhibitors
Jurkat cells were treated with YG32 (2 or 10 Wg/ml) and CH11 (10
or 50 ng/ml) in the indicated combinations. Caspase inhibitors (20 WM
z-VAD-fmk or 50 WM z-IETD-fmk) were added to the media to
evaluate their e¡ects. The cells were harvested and analyzed after 5 h.
2.5. Western blot analysis
Sodium dodecyl sulfate (SDS)-stable Fas microaggregates were an-
alyzed as described previously [29]. Brie£y, aliquots of 5U106 cells
were stimulated with anti-CD99 mAb (2 or 10 Wg/ml YG32) for 30
min or 2 h at 37‡C. The cells were washed with phosphate-bu¡ered
saline (PBS) and lysed in bu¡er containing 50 mM HEPES (pH 7.4),
150 mM NaCl, 10 mM NaF, 10 mM iodoacetamide, 200 WM
Na3VO4, and 1% NP-40. The post-nuclear supernatants were loaded
onto SDS^polyacrylamide gel electrophoresis gels, separated by elec-
trophoresis, and transferred onto polyvinylidene di£uoride Immobilon
Fig. 1. Comparison of death responses mediated by mAbs YG32 and DN16, recognizing di¡erent epitopes and domains on the CD99 molecule.
A: Schematic diagram of the CD99 molecule [16,26]. Locations of epitopes of anti-CD99 mAbs are shown. S, signal sequence; E, extracellular
domain; TM, transmembrane domain; C, cytoplasmic domain. B: Jurkat T cells were stimulated with DN16 anti-CD99 mAb (10 Wg/ml) and
YG32 anti-CD99 mAb (10 Wg/ml) for 30 min in the presence (right panels) or absence (left panels) of secondary Ab (20 Wg/ml of anti-mouse
Ig) (C; no stimulation, 2P ; secondary Ab). C: Jurkat cells were cultured with mAb as indicated for 5 h. Cell death was assayed by annexin V
staining. Speci¢c cell death (% cell death) was calculated as a normalized value as follows: 100U[% of apoptotic cells (stimulated)3% of apo-
ptotic cells (unstimulated)]/% of apoptotic cells (unstimulated). The real percentages of dead cells were assayed by trypan blue exclusion and
the ranges are shown.
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membranes (Millipore, Bedford, MA, USA). The blotted membranes
were incubated with C20 Ab against Fas followed by HRP-conjugated
anti-mouse Ab. The speci¢c bands were visualized using an Enhanced
Chemiluminescent kit from Amersham Pharmacia Biotech (Bucking-
hamshire, UK).
2.6. Immuno£uorescence staining and confocal analysis
Jurkat cells were stimulated with anti-CD99 mAb. After washing in
cold PBS, the cells were adhered to poly-L-lysine-coated slides. The
cells were ¢xed with 4% paraformaldehyde in PBS for 15 min at room
temperature, and incubated with biotinylated anti-Fas mAb (clone
DX2, BD Biosciences) and streptavidin-Alexa 488 (Molecular Probes,
Eugene, OR, USA). The stained preparations were mounted with
coverslides and observed with a confocal microscope (Radiance
2000, Bio-Rad Laboratories, Hercules, CA, USA).
3. Results
3.1. Treatment with the anti-CD99 mAb YG32 induces
homotypic aggregation, but does not induce apoptosis in
Jurkat T cells
Two anti-CD99 mAbs, DN16 and YG32, were used to
study the functional role of the CD99 molecule in T cell biol-
ogy. Based on previous studies, a schematic diagram of the
CD99 molecule with binding epitopes of mAbs is shown in
Fig. 1A. We examined whether homotypic aggregation was
induced by incubating Jurkat T cells with each anti-CD99
antibody in the presence or absence of a second cross-linking
Ab. As reported previously [21], ligation via the DN16 epitope
induced homotypic aggregation (Fig. 1B). Likewise, signaling
via the YG32 epitope of the CD99 molecule also resulted in
homotypic aggregation of Jurkat T cells (Fig. 1B) suggesting
that both epitopes play roles in T cell functioning. In addition,
with both mAbs, CD99-induced homotypic aggregation oc-
curred, even in the absence of a second cross-linking Ab
(Fig. 1B).
As we were interested in the role of CD99 epitopes in T cell
death, we next examined whether both mAbs triggered the
apoptotic signaling pathway. In fact, CD99 engagement has
been reported to induce apoptosis in T cells using various
mAbs and a second cross-linking Ab [13,16,19,20]. In this
study, as no second cross-linking Ab was needed for homo-
typic aggregation (Fig. 1B), only the primary mAb, DN16 or
YG32, was added to induce apoptosis in Jurkat cells and then
£ow cytometric analysis was used to detect apoptotic cells.
Ligation of the CD99 molecule via the DN16 epitope success-
fully induced apoptosis, but no apoptosis was observed in
YG32-treated Jurkat cells (Fig. 1C) implying that each epi-
tope of the CD99 molecule has a distinct function in T cell
death. Similar results were seen in the presence of a second
cross-linking Ab (data not shown).
3.2. Signaling via the YG32 epitope enhances Fas-mediated cell
death in Jurkat cells
Although YG32 signaling failed to induce apoptosis in Jur-
kat cells, we examined the involvement of the YG32 epitope
in T cell death. Jurkat cells are widely used to study Fas-
mediated cell death. Therefore, we evaluated the role of the
YG32 epitope in Fas-mediated cell death. Cells treated with
an agonistic anti-Fas Ab, CH11, were treated with or without
YG32 mAb and the apoptosis was analyzed by £ow cytome-
try (Fig. 2A,B). Ligation of the YG32 epitope in the CD99
molecule augmented the degree of Fas-mediated apoptosis
(Fig. 2A,B). This was con¢rmed by trypan blue exclusion
(Fig. 2C) and measuring the reduction in the mitochondrial
membrane potential, vim (Fig. 3). In addition, YG32-en-
Fig. 2. Fas-mediated apoptosis was increased by CD99 ligation through the YG32 epitope. Addition of the anti-CD99 mAb YG32 enhanced
the cell death induced by Fas ligation. A: Jurkat cells (2U105/ml) were incubated for 5 h with mAbs (YG32, 10 Wg/ml; CH11, 50 ng/ml) as in-
dicated combinations and stained with annexin V and 7-AAD. Representative result of three separate experiments. B: The degree of cell death
was measured by annexin V staining after 5 h. After 5 h incubation with indicated combinations, apoptotic cells were measured by annexin V
staining. Speci¢c cell death (% of annexin V-positive cells) was calculated as a normalized value as described in Fig. 1C. The real percentages
of annexin V-positive apoptotic cells are as follows. Control, 16.1 T 4.7; YG32 2 Wg/ml, 13.4T 2.9; YG32 10 Wg/ml, 17.2T 3.9; CH11 10 ng/ml,
18.4T 2.8; CH11 10 ng/ml+YG32 2 Wg/ml, 28.4T 5.2; CH11 10 ng/ml+YG32 10 Wg/ml, 35.5T 6.4; CH11 50 ng/ml, 32.4T 9.98; CH11 50 ng/
ml+YG32 2 Wg/ml, 45.84T 14.8; CH11 50 ng/ml+YG32 10 Wg/ml, 54.0T 10.3. C: The real percentages of dead cells were measured by trypan
blue exclusion. Jurkat cells were incubated with mAbs (YG32, 10 Wg/ml; CH11, 50 ng/ml) for 18 h and the dead cells were calculated.
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hanced cell death even occurred with 10 ng of anti-Fas Ab,
which did not cause apoptosis of Jurkat cells in 5 h incubation
(Fig. 2B).
We next examined whether ligation via the YG32 epitope
up-regulated the level of Fas expression in Jurkat cells. With
YG32 treatment, FACS analysis showed no di¡erence in the
Fas expression on the cell surface as compared with control
cells (data not shown). Reverse transcription polymerase
chain reaction (RT-PCR) analysis also revealed that the mes-
sengers for the Fas molecule were identical in both untreated
and YG32-treated Jurkat cells (data not shown). These obser-
vations suggest that the augmentation of Fas-mediated cell
death was not due to the up-regulation of Fas expression.
3.3. The augmentation of Fas-mediated apoptosis via the YG32
epitope is related to the caspase activation
Caspases play a pivotal role in Fas-mediated apoptosis. On
binding to cognate ligands or agonistic antibodies, Fas aggre-
gates initiate the activation of caspase 8, which is followed by
a cascade of caspase activation including caspase 3. We mea-
sured caspase 3 activities upon treatment of mAbs, CH11 and/
or YG32, if there is an augmentation of caspase 3 functions
by CD99 ligation via the YG32 epitope. As shown in Fig. 4A,
though the YG32 signal itself did not induce caspase 3 acti-
vation, it was able to augment the activation of caspase 3 in
Fig. 3. Augmentation of reduction in vim in Fas-mediated apopto-
sis by CD99 ligation. The CH11-induced cell death was increased
by YG32 mAb treatment, and the degree of augmentation was par-
allel to the amount of mAb added. Jurkat cells were incubated with
mAbs for 5 h, and cell death was assayed by DiOC6 staining.
Fig. 4. Activation of caspase 3 and the e¡ect of caspase inhibitors on YG32-ampli¢ed apoptosis in Jurkat cells. A: Activation of caspase 3 was
measured upon ligation of CH11 and/or YG32 mAbs (CH11, 50 ng/ml; YG32, 10 Wg/ml). Jurkat cells were incubated with mAbs as indicated
and the cellular extracts were collected after 5 or 8 h. Caspase 3 activity was assayed as described in Section 2. B: Cells (2U105/ml) were incu-
bated with YG32 (10 Wg/ml) and/or CH11 (50 ng/ml) for 5 h. 20 WM of z-VAD-fmk or 50 WM of z-IETD-fmk was added to block the caspase
activation. Speci¢c cell death (% cell death) was calculated as a normalized value as described in Fig. 1C. After 5 h incubation, the degree of
apoptosis was determined by using annexin V staining and analyzed by £ow cytometry. The real percentages of annexin V-positive apoptotic
cells are shown as numbers.
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the Fas signaling pathway. We next used caspase inhibitors to
elucidate whether the inhibition of caspase activation could
prevent the Jurkat cells from apoptosis by engagement of
both Fas and CD99. We ¢rst used a pan-caspase inhibitor,
z-VAD-fmk, and found that the YG32-mediated augmenta-
tion of Fas-mediated cell death was completely inhibited
(Fig. 4B). Next, a caspase 8 inhibitor, z-IETD-fmk, was
used to block the early events in the Fas pathway. As shown
in Fig. 4B, the caspase 8 inhibitor also blocked the YG32-
mediated augmentation of Fas-mediated cell death, as well as
Fas-mediated cell death itself. These ¢ndings imply that YG32
itself could not induce the apoptosis of Jurkat cells, when the
Fas-mediated signal is blocked, con¢rming that YG32-medi-
ated apoptosis of Jurkat cells is dependent on Fas signal.
3.4. The YG32/CD99 signal induces the aggregation of
Fas molecules
When Fas interacts with FasL or agonistic anti-Fas Abs,
Fas molecules are trimerized and caspase 8 is subsequently
activated [30]. As the YG32 treatment did not a¡ect the ex-
pression of Fas molecules on the surface of Jurkat cells, we
assessed whether YG32 ligation enhanced Fas-mediated apo-
ptosis via an e¡ect on Fas aggregation. For this evaluation,
Jurkat cells were treated with 2 or 10 Wg of YG32 mAb for 30
min or 2 h, and Western blot and confocal microscope anal-
yses were performed (Fig. 5A,B). As shown in Fig. 5A, stim-
ulation of Jurkat cells with anti-CD99 mAb (YG32, 2 or 10
Wg/ml) induced the formation of SDS- and 2-ME-stable, high
Mr aggregates (s 200 kDa) of Fas antigen, as reported pre-
viously [31^33]. The formation of the high Mr aggregates in-
creased with time and the amount of mAb added, while no
aggregation was observed in the control cells treated with
irrelevant mAb (Fig. 5A). These results indicate that CD99
ligation via the YG32 epitope induced Fas aggregation in the
absence of Fas engagement. This was con¢rmed by confocal
analysis. After Jurkat cells were treated with the anti-CD99
mAb YG32 for the indicated times, Fas molecules were visu-
alized and analyzed by confocal microscopy. Patch-shaped
Fas aggregates were detected when cells were treated with
YG32 mAb, while none were noted in the negative controls
(Fig. 5B). In particular, almost all of the cells showed clumped
patches of Fas molecules after 2 h of stimulation (Fig. 5B).
Therefore, the CD99 signal via the YG32 epitope induced
aggregation of Fas molecules in Jurkat T cells without FasL
or agonistic anti-Fas mAb treatment.
4. Discussion
In this study, we dissected the functional role of each CD99
epitope in T cell biology. Although the function of the CD99
molecule is still unclear, the CD99 antigen has been implicated
in various cellular processes, including homotypic aggrega-
tion, apoptosis [16,17,21], vesicular protein transport [20,
22,28], activation of mitogen-activated protein (MAP) kinase
[21], up-regulation of VLA-4-mediated adhesion of T cells
to endothelium [23], Th1 cell di¡erentiation [24], and mi-
gration of monocytes across endothelial cells into an in£am-
matory site [25]. Moreover, apoptosis induced via the CD99
molecule has been demonstrated in thymocytes [16], Ewing’s
sarcoma cells [17], and Jurkat T cells [13]. In particular,
Pettersen et al. [13] investigated the role of CD99 epitopes
in T cell death using a number of mAbs to CD99 antigen
and found that each epitope possessed a distinct function in
apoptosis.
Previously, we described two mAbs recognizing the CD99
molecule, DN16 and YG32, which appear to recognize di¡er-
ent epitopes of the CD99 antigen (Fig. 1A) [26]. In this study,
we examined the role of the YG32 epitope in T cell death, as
most of our work has been restricted to the DN16 epitope. In
fact, the a⁄nity of YG32 mAb to CD99-GST fusion protein
seemed to be stronger that that of DN16 mAb, although it is
not certain if the a⁄nity di¡erences are also applicable to the
natural form of CD99 [26]. Consequently, we focused on the
function of the YG32 epitope in the CD99 molecule. Unlike
DN16, the YG32 epitope did not seem to act as a death
receptor in Jurkat cells (Fig. 1C). This was interesting as the
YG32 signal successfully induced homotypic aggregation even
in the absence of a second cross-linking Ab (Fig. 1B) and led
to the activation of MAP kinase, as did the DN16 signal [21].
Proper activation of death receptors plays a major role in
the regulation of T cell development and function. Of these,
Fas plays an important role in regulating the immune re-
sponse and controlling peripheral B and T cell survival, which
is critical for the maintenance of immune cell homeostasis
[34]. The contribution of the Fas-mediated cell death pathway
to controlling the peripheral T cell immune response has been
well characterized [35^37]. In addition, Jurkat cells are widely
used to investigate Fas-mediated cell death. On binding to
cognate ligands or agonistic antibodies, the Fas receptors
homo-oligomerize via the death domain [1], and the involve-
ment of a lipid raft in Fas-mediated cell death was recently
Fig. 5. YG32-induced aggregation of the Fas molecules. A: Jurkat
cells (5U106/ml) were incubated with anti-CD99 (2 Wg/ml or 10 Wg/
ml) for 30 min and 2 h. Total cell lysates were prepared and ana-
lyzed as described in Section 2. B: Jurkat cells were treated with
anti-CD99 mAb, YG32, for 30 min and 2 h. Fas aggregates were
detected by staining cells with biotinylated anti-Fas mAb and strep-
tavidin-Alexa 488. Stained cells were analyzed by confocal microsco-
py. Prominent patch-like aggregations of Fas were observed in anti-
CD99 mAb-treated Jurkat cells.
FEBS 27830 5-11-03 Cyaan Magenta Geel Zwart
K.C. Jung et al./FEBS Letters 554 (2003) 478^484482
demonstrated [38,39]. The YG32 signal appears to play a role
in the vesicular transport of transmembrane proteins [22] and
lipid rafts from the intracellular location to the cell surface
[28]. In addition, CD99 ligation appeared to be involved in
T cell death [13,16,19,20]. As the CD99 molecule plays a role
in a number of biological functions, we tested if the YG32
epitope could also act as a death receptor. However, unlike
the DN16 epitope, YG32 ligation failed to induce apoptosis in
Jurkat cells. As the Jurkat cells are sensitive to Fas-mediated
cell death, we next examined whether the YG32 epitope is
involved in Fas-mediated cell death. CD99-mediated cell
death has been reported to be Fas-independent in thymocytes
[16] and leukemic cell lines [13]. As shown in Fig. 2, although
the YG32 signal alone did not induce apoptosis, it enhanced
Fas-mediated cell death in Jurkat cells, implying that the role
of the YG32 epitope di¡ers from that of DN16. Pettersen et
al. [13] also reported that a distinct epitope of CD99 recog-
nized by clone Ad20 possessed a speci¢c role in T cell death,
while another epitope of CD99 recognized by clone O662
failed to kill Jurkat T cells. By contrast, Bernard et al. [16]
reported that engagement of CD99 by O662 antibody had
been known to induce the apoptosis of immature thymocytes.
These results suggest that each CD99 epitope has a distinct
role in T cell function.
Fas ligation via FasL or agonistic anti-Fas Ab induces Fas
oligomerization [4,5], recruits adapter and e¡ector cytoplas-
mic proteins to the cell surface [1], and results in caspase
activation. Next, we considered which steps in the Fas path-
way are the targets of the YG32 signal in Jurkat cells. We ¢rst
considered the possibility that the expression of Fas molecules
on the surface of Jurkat cells is enhanced by the YG32 treat-
ment. However, £ow cytometry and RT-PCR analyses re-
vealed that this was not the case (data not shown). Thus,
we next assessed whether YG32 signal induced oligomeriza-
tion of Fas molecules. As shown in Fig. 5A,B, oligomerized
Fas molecules were readily observed on treatment with the
anti-CD99 mAb YG32. We reported previously that the
CD99 signal is involved in the vesicular transport of trans-
membrane proteins [22] and lipid rafts [28], and the involve-
ment of lipid rafts in Fas-mediated cell death was demon-
strated recently. Therefore, we investigated whether Fas
oligomers resided in lipid rafts of the cell membrane. When
stained simultaneously with cholera toxin, Fas oligomers did
not appear to reside in the lipid raft (data not shown). This
implies that the e¡ect of the YG32 signal on Fas signaling
di¡ers from that on vesicular transport of the lipid raft [28].
In summary, the YG32 epitope of CD99 antigen conveys a
di¡erent signal from that of DN16, as no apoptosis occurred
on YG32 ligation. In addition, the YG32 signal activates Fas
oligomerization, enhancing Fas-mediated cell death in T cells
via an as yet unde¢ned pathway. Therefore, the CD99 mole-
cule can induce caspase-independent non-classical apoptosis
and is involved in classical receptor-mediated apoptosis in
T cells. It would be interesting to determine whether the
YG32 epitope of the CD99 molecule enhances physiological
activation-induced cell death.
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